Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

Laboratory

Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...

OxyContin

OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...

Lyxumia

Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is re...

International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5

OSLO, NORWAY -- (Marketwire) -- 06/07/12 -- Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine ca...

Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial

OSLO, NORWAY -- (Marketwire) -- 12/05/12 -- Bionor Pharma ASA (OSLO: BIONOR) News Summary Bionor Pharma ASA (OSLO: BIONOR) announced today that the new reboost study of patients from the previousl...

Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting ...

Bionor Researchers Report Findings at AIDS 2012 "Towards an HIV Cure" Pre-Conference Symposium

Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer

OSLO, NORWAY -- (Marketwire) -- 01/29/13 -- Bionor Pharma ASA (OSLO: BIONOR) today announced that Anker Lundemose, MD, PhD, DMSc (Medical Microbiology), has been appointed as President and CEO of Bio...

Study of Vacc-4x Combined With Celgene's Revlimid(R) (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin

OSLO, NORWAY -- (Marketwire) -- 08/13/12 -- Bionor Pharma ASA (OSLO: BIONOR) News Summary Bionor Pharma ASA (OSLO: BIONOR) announced today that the clinical trial application for the placebo-contro...

Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS

WASHINGTON, DC and OSLO, NORWAY -- (Marketwire) -- 07/20/12 -- Bionor Pharma ASA (OSLO: BIONOR) News summary Bionor Pharma ASA (OSLO: BIONOR) announced today that the Company is presenting its immu...

HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma

OSLO, NORWAY -- (Marketwire) -- 07/17/12 -- Bionor Pharma ASA (OSLO: BIONOR) announced today that the HIV expert from the UK based St. George's University of London, Professor Angus "Gus" Dalgleish i...

International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5

Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42.

Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.

Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...

Is pharma running out of brainy ideas?

Big pharma moves from 'blockbusters' to 'niche busters'.

China spurs pharma innovation.